<DOC>
	<DOCNO>NCT01918124</DOCNO>
	<brief_summary>This phase II clinical trial design assess feasibility , safety , toxicity , recurrence survival pattern TP CAP chemotherapy combine adjuvant radiation patient high-risk endometrial cancer .</brief_summary>
	<brief_title>A Phase II Trial Adjuvant Radiotherapy Combined With Chemotherapy Patients With High-risk Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Prosthesis Failure</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients must hysterectomy ( total abdominal , vaginal hysterectomy , laparoscopicassisted vaginal hysterectomy ) modify radical hysterectomy radical hysterectomy bilateral salpingooophorectomy 8 week prior start radiation therapy . Additional surgical staging procedure permissible require . Risk factor : patient must fit one following : Pelvic lymph node metastasis Paraaortic lymph node metastasis Grade 3 myometrial invasion &gt; 50 % With stromal invasion cervix Known extrauterine disease ( exclude second primary ) confine pelvis . High risk pathological type include : uterine papillary serous carcinoma , clear cell carcinoma , squamous cell carcinoma , undifferentiated carcinoma , No known gross residual disease , distant metastasis . Eastern Cooperative Oncology Group ( ECOG ) score &lt; =2 ; Age 18~75 . White Blood Cell ( WBC ) ≥4000/mm3 , granulocytes ≥1500/mcl , platelets≥100,000/mcl . Acceptable hepatic renal function : creatinine &lt; =1.4 mg % , bilirubin serum glutamate oxaloacetate transaminase ( SGOT ) &lt; =2*normal . No medical contraindication chemotherapy , radiation therapy . Studyspecific sign informed consent . Prior pelvic radiation therapy . Positive peritoneal cytology stage IIIa ( FIGO 1998 ) . With history malignancy less 5 year . With gross residual disease , distant metastasis . With endometrioid endometrial carcinoma risk factor : myometrial invasion &lt; 50 % Grade 1~2 , myometrial invasion &gt; 50 % With serious internal disease affect design treatment With psychotic disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>disease free survival , overall survival</keyword>
</DOC>